Systematic Review and Meta-analysis of Pirfenidone, Nintedanib, and Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Background: The comparative efficacy of pirfenidone, nintedanib, and pamrevlumab in slowing the rate of forced vital capacity (FVC) decline and mortality in patients with idiopathic pulmonary fibrosis (IPF) is unknown. Objective: To perform a systematic review and meta-analysis (MA) of these drugs for IPF. Methods: We searched CENTRAL, PubMed, EMBASE, ClincalTrials.gov, and the World Health Organization’s registry databases up to March 2020. Phase II/III randomized controlled trials in adults with IPF were eligible. The random-effect model was implemented calculating the effect size and respective 95% CI as Cohen’s d for change from baseline FVC (in percentage predicted and liters) and odds ratio (OR) for 10% reduction in FVC and all-cause mortality (ACM). Results: Six studies were included in the MA. For change from baseline in percentage predicted FVC, the MA indicated that the 3 drugs were more effective than placebo (pirfenidone: d=3.30%, 95% CI=2.15-4.45; nintedanib: d=3.15%, 95% CI=2.35-3.95; pamrevlumab: d=4.30%, 95% CI=0.45-8.15). These results are superimposable to those relating to change from baseline FVC in liters (pirfenidone: d=0.09L, 95% CI=0.04-0.14; nintedanib: d=0.13L, 95% CI=0.10-0.16; pamrevlumab: d=0.20L, 95% CI=0.05-0.35). Each drug had a positive effect on 10% reduction in FVC (pirfenidone: OR=0.57, 95% CI=0.45-0.74; nintedanib: OR=0.66, 95% CI=0.51-0.85; pamrevlumab: OR=0.24, 95% CI=0.08-0.73), but only pirfenidone showed an effect on ACM (OR=0.50; 95% CI=0.31-0.83). Conclusion and Relevance: This MA provided encouraging results on pamrevlumab efficacy in slowing the decline in FVC compared with pirfenidone and nintedanib. Actually, in phase 3, it could become a potential IPF treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A series of systematic reviews and meta-analyses confirmed the efficacy and safety of pirfenidone in the treatment of IPF [27–33].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [29]
Citations
Cites
The Measurement of Observer Agreement for Categorical Data
Landis, J. R., & Koch, G. G. (1977) · Biometrics · doi:10.2307/2529310 · Cited by 81,148
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 34,787
Statistical Power Analysis for the Behavioral Sciences
Cohen, J. (2013) · doi:10.4324/9780203771587 · Cited by 25,373
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Richeldi, L., Collard, H. R., & Jones, M. G. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30866-8 · Cited by 2,020
Raghu, G., Rochwerg, B., Zhang, Y., Garcia, C. A. C., Azuma, A., Behr, J., Brozek, J. L., Collard, H. R., Cunningham, W., Homma, S., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201506-1063st · Cited by 1,916
Cited by
Idiopathic pulmonary fibrosis: Current and future treatment
Glass, D. S., Grossfeld, D., Renna, H. A., Agarwala, P., Spiegler, P., DeLeon, J., & Reiss, A. B. (2022) · The Clinical Respiratory Journal · doi:10.1111/crj.13466 · Cited by 314
“gov identifier NCT03955146), a phase 3 randomized, double-blind, placebo-controlled, multicenter clinical trial with plans to enroll 340 subjects, is ongoing and will evaluate efficacy and safety of pamrevlumab over 52 weeks.(129,130)”
BackgroundAntar, S. A., Saleh, M. A., & Al-Karmalawy, A. A. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121048 · Cited by 76
Medical treatments for idiopathic pulmonary fibrosis: a systematic review and network meta-analysis
Pitre, T., Mah, J. C., Helmeczi, W., Khalid, M. F., Cui, S., Zhang, M., Husnudinov, R., Su, J. S., Banfield, L. E., Guy, B., et al. (2022) · Thorax · doi:10.1136/thoraxjnl-2021-217976 · Cited by 72
Cheng, P. T. W., Kaltenbach, R. F., Zhang, H., Shi, J., Tao, S., Li, J., Kennedy, L. J., Walker, S. J., Shi, Y., Wang, Y., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01256 · Cited by 61
Mackintosh, J. A., Keir, G. J., Troy, L. K., Holland, A. E., Grainge, C., Chambers, D. C., Sandford, D., Jo, H. E., Glaspole, I., WILSHER, M. L., et al. (2024) · Respirology · doi:10.1111/resp.14656 · Cited by 60
Guo, H., Sun, J., Zhang, S., Nie, Y., Zhou, S., & Zeng, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1205948 · Cited by 41
Antifibrotics and Reduced Mortality in Idiopathic Pulmonary Fibrosis: Immortal Time Bias
Suissa, S., & Suissa, K. (2023) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202207-1301le · Cited by 36
“Indeed, whereas a metaanalysis concluded that neither pirfenidone nor nintedanib is associated with lower mortality (2), others found reduced mortality only with nintedanib but not pirfenidone (3), or vice-versa (6).”
BackgroundFederal clinical guidelines on diagnosis and treatment of idiopathic pulmonary fibrosis
Avdeev, S. N., Айсанов, З. Р., Belevskiy, А. S., Ilkovich, M. M., Коган, Е. А., Мержоева, З. М., Petrov, D., Samsonova, M. V., Terpigorev, S. A., Трушенко, Н. В., et al. (2022) · PULMONOLOGIYA · doi:10.18093/0869-0189-2022-32-3-473-495 · Cited by 32
Chen, C., Lin, H.-C., Wang, Y., Wang, C., Lin, Y. S., & Lai, C. (2021) · PLoS ONE · doi:10.1371/journal.pone.0251636 · Cited by 31
Molecular mechanisms of ovarian fibrosis
Edepli, B. G., & Yaba, A. (2025) · Molecular Human Reproduction · doi:10.1093/molehr/gaaf058 · Cited by 29
“Pirfenidone, a drug approved by the FDA for pulmonary fibrosis, exhibits antifibrotic activity primarily by reducing TGF-β 1 expression (Meyer and Decker, 2017; Di Martino et al. , 2021).”
Idiopathic pulmonary fibrosis: Diagnosis, biomarkers and newer treatment protocols
Patel, H., Shah, J. R., Patel, D., Avanthika, C., Jhaveri, S., & Gor, K. (2022) · Disease-a-Month · doi:10.1016/j.disamonth.2022.101484 · Cited by 25
Regulator of Cell Cycle Protein (RGCC/RGC-32) Protects Against Pulmonary Fibrosis
Luzina, I. G., Rus, V., Lockatell, V., Courneya, J.-P., Hampton, B., Fishelevich, R., Misharin, A. V., Todd, N. W., Badea, T. C., Rus, H., et al. (2021) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2021-0022oc · Cited by 19
Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF)
Aribindi, K., Liu, G. Y., & Albertson, T. E. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2396121 · Cited by 17
“Systematic review/meta-analysis of six studies that included pamrevlumab in IPF patients and a separate review stressed its encouraging results and the appearance of efficacy and safety [29,71].”
Yang, X., Huang, X., Chen, Z., Xu, A.-L., Zhou, H., Bi, X., Yan, P., & Xie, Y. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e13598 · Cited by 23
The Impact of Inflammatory Immune Reactions of the Vascular Niche on Organ Fibrosis
Zhou, H., Sui, H. X., Zhao, Y.-J., Qian, H.-J., Yang, N., Liu, L., Guan, Q., Zhou, Y., Lin, H., & Wang, D. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.750509 · Cited by 16
Sgalla, G., Simonetti, J., Cortese, S., & Richeldi, L. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2173061 · Cited by 19
Xiao, T., Gao, D., Gu, X., Zhang, Y., Zhu, Y., Zhang, Z., He, Y., Wei, L., Li, H., Zhou, H., et al. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175981 · Cited by 16
Treatment of Idiopathic Pulmonary Fibrosis
Abuserewa, S. T. H., Duff, R., & Becker, G. (2021) · Cureus · doi:10.7759/cureus.15360 · Cited by 18
“It may become a potential IPF treatment [67].”
BackgroundSenhaji, L., Senhaji, N., Abbassi, M., Karhate, M., Serraj, M., Biaze, M. E., Benjelloun, M. C., Ouldim, K., Bouguenouch, L., & Amara, B. (2026) · Biomedicines · doi:10.3390/biomedicines14010090 · Cited by 15
“Conversely, if the patient has skin problems, Pirfenidone should be avoided and Nintedanib should be preferred [111].”
Provenzani, A., Vinci, D. L., Alaimo, M., Maria, S. D., Tuzzolino, F., Floridia, G., Stefano, R. D., Carollo, A., Callari, A., Polidori, P., et al. (2025) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986251341645 · Cited by 17
“19 20–22 The CAPACITY and ASCEND trials assessed the impact of pirfenidone on the progression of IPF and found a favorable risk–benefit profile.”
Self-citationCurrent and prospective applications of exosomal microRNAs in pulmonary fibrosis (Review)
Yang, T., Wang, J., Zhao, J., & Liu, Y. (2022) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2022.5092 · Cited by 12
“A previous meta‐analysis of the use of pirfenidone, nintedanib and pamrevlumab (monoclonal antibody targeting connective tissue growth factor, FG‐3109) for the treatment of patients with IPF suggested that pamrevlumab significantly improved pulmonary function and was effective in attenu‐ ating the decline in forced vi…”
MethodEffect of Antifibrotic Use on Mortality in Patients with Idiopathic Pulmonary Fibrosis
Xu, H., Hui, S. L., Lee, J. S., Zhang, Z., & Boente, R. (2024) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202312-1054oc · Cited by 10
Sun, C., Liu, H., Han, J., Chi, B., Koga, Y., Afshar, K., & Liu, X. (2024) · Journal of Thoracic Disease · doi:10.21037/jtd-24-28 · Cited by 7
“Although the antiproliferative drugs, pirfenidone and nintedanib, can slow progression of lung function and lessen exacerbation events, the therapeutic effect is limited (3).”
BackgroundHozumi, H., Miyashita, K., Nakatani, E., Inoue, Y., Yasui, H., Suzuki, Y., Karayama, M., Furuhashi, K., Enomoto, N., Fujisawa, T., et al. (2024) · Respiratory Research · doi:10.1186/s12931-024-02922-y · Cited by 10
Inhibition of glutamine transporter ASCT2 mitigates bleomycin-induced pulmonary fibrosis in mice
Lian, N., Jin, H., Zhu, W., Zhang, C., Qi, Y., Jiang, M., Mao, J., Lu, X., Zhao, F., Xi, B., et al. (2022) · Acta Histochemica · doi:10.1016/j.acthis.2022.151961 · Cited by 8
Kotani, T., Ikemoto, M., Matsuda, S., Masutani, R., & Takeuchi, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179669 · Cited by 6
“Pirfenidone and nintedanib have been used to suppress the progression of fibrosis; however, their effects are limited [7].”
BackgroundHematopoietic Stem Cells Transplant (HSCT)-Related Chronic Pulmonary Diseases: An Overview
Traunero, A., Peri, F., Badina, L., Amaddeo, A., Zuliani, E., Maschio, M., Barbi, E., & Ghirardo, S. (2023) · Children · doi:10.3390/children10091535 · Cited by 6
“Drugs are generally intended to slow the process rather than reverse it, which seems unlikely due to its pathogenesis [52].”
BackgroundKokubu, H., Takeuchi, S., Tozawa, T., Hisada, S., Yamada, Y., Itoh, Y., & Kodera, M. (2023) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.14611 · Cited by 2
Bolger, G. B. (2025) · Life · doi:10.3390/life15101600 · Cited by 6
Wang, C., Chen, T., Mu, Y., Liang, X., Xiong, K., Ai, L., Gu, Y., Fan, X., & Liang, H. (2022) · Database · doi:10.1093/database/baac095 · Cited by 3
“For example, idiopathic pulmonary fibrosis (IPF) is a chronic progressive disease characterized by destroyed pulmonary alveolar architecture (4, 5).”
BackgroundAntifibrotic Drugs for COVID-19: From Orphan Drugs to Blockbusters?
Corrie, L., Muzaffar-Ur-Rehman, M., Kukatil, L., Devasari, M., & Shirisha, A. (2021) · Current Respiratory Medicine Reviews · doi:10.2174/1573398x17666210304100043 · Cited by 2
An Eternal Dilemma: Exposing the Impact of Immortal Time Bias on Antifibrotic Effectiveness
Kyle, A. R., & Dempsey, T. M. (2024) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202407-717ed · Cited by 2
“Although there is a lack of clinical trial evidence supporting a mortality bene fi t for the anti fi brotics, observational studies (as well as pooled clinical trial analyses) have repeatedly suggested one may exist (4 – 10).”
BackgroundNovara, M. E., Chirulli, M., Vitulo, P., Carollo, A., & Provenzani, A. (2026) · Biomedicines · doi:10.3390/biomedicines14061293 · Cited by 1
Self-citationAdams, R. L., Maher, A., Gale, N. K., Crawshaw, A., THICKETT, D. R., & Turner, A. M. (2025) · Health Technology Assessment · doi:10.3310/twks4194 · Cited by 1
Nintedanib, Pirfenidone and Pirfenidone Versus Nintedanib: A Systematic Review And Meta-AnalysisPreprint
Pitre, T., Husnudinov, R., Khalid, M. F., Zhang, M. C., Cui, S., Tran, J., Mah, J. C., Helmeczi, W., Su, J. S., Jones, A., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-589439/v1
Prospects for Treatment of Idiopathic Pulmonary Fibrosis
Mustafin, R. N. (2022) · The Russian Archives of Internal Medicine · doi:10.20514/2226-6704-2022-12-4-267-275 · Cited by 1
Idiopathic pulmonary fibrosis - novel approach on future treatment
PACEK, K., Piekarska, M., Pikulicka, A., Jedlina, K., SZULC, I., Kasperski, R., SWACHA, W., & Makowska, K. (2023) · Journal of Education Health and Sport · doi:10.12775/jehs.2023.13.02.039
Qiaolongbatu, X., Wu, Z., Qu, H., Shen, R., Wang, Y., Li, W., Zhou, C.-Y., Wang, Y., Fan, G., & Wu, J. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4866524
Xinping, Y., Wang, Y., Qiaolongbatu, X., Qu, H., Li, Z., Wu, J., & Wu, Z. (2025) · Research Square · doi:10.21203/rs.3.rs-7966320/v1
Hozumi, H., Miyashita, K., Nakatani, E., Inoue, Y., Yasui, H., Suzuki, Y., Karayama, M., Furuhashi, K., Enomoto, N., Fujisawa, T., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26420374
國府, 拓., Kokubu, H., Takeuchi, S., Tozawa, T., Hisada, S., Yamada, Y., ITOH, Y., & Kodera, M. (2023) · Institutional Repositories DataBase (IRDB)
Mortality Prediction Using Systemic Inflammation Based Biomarkers in Idiopathic Pulmonary Fibrosis
ERİNÇ, A., Kirac, A., Gul, S. K., & Çetınkaya, E. (2026) · OSMANGAZİ JOURNAL OF MEDICINE · doi:10.20515/otd.1841308
Lang, C., Wu, J., & Wang, N. (2026) · Molecular Genetics and Genomics · doi:10.1007/s00438-026-02473-5
Yang, X., Wang, Y., Qiaolongbatu, X., Qu, H., Li, Z., Wu, J., & Wu, Z. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05872-y
Hashimoto, K., Arioka, M., Morimoto, T., Wang, Y., Ito, K., Ishikane, S., Yatera, K., & Takahashi‐Yanaga, F. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119905
Research on the role and mechanism of SLC7A5 in idiopathic pulmonary fibrosis
Wang, M., Yu, Y., Liu, Z., Xu, D., Li, Y., Zou, X., Shan, N., Liu, X., Shi, C., & Chen, H. (2026) · Molecular Medicine Reports · doi:10.3892/mmr.2026.14034
“However, treatments using these drugs have demonstrated a number of adverse reactions, which forces patients to reduce the dosage and in turn affects treatment outcomes (5,63).”
BindingDB Entry 50014961: Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA
BindingDB (2023) · UC San Diego · doi:10.7270/q2pz5dp9
Metadata
- Authors
- Di Martino, E., Provenzani, A., Vitulo, P., & Polidori, P.
- Affiliations
- University of Palermo, Italy
- Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione (IT)
- Venue
- Annals of Pharmacotherapy
- Publisher
- SAGE Publications
- Published
- 2020-10-15
- Volume
- 55
- Issue
- 6
- Pages
- 723-731
- ISSN
- 0012-6578 (ISSN-L)
- 1060-0280
- 1542-6270
- OpenAlex
- W3093240978
- Cited by
- 46
- References
- 28
- Citations by year
- 2026: 7 · 2025: 5 · 2024: 8 · 2023: 8 · 2022: 11 · 2021: 7
- FWCI
- 0.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Annals of Pharmacotherapy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- idiopathic pulmonary fibrosis, pirfenidone, nintedanib, forced vital capacity decline, all-cause mortality, antifibrotic therapy, drug efficacy comparison, antifibrotic agents, anti-PD-1 therapy
- MeSH terms
- Humans, Indoles, Pyridones, Treatment Outcome, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.